Cargando…

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

As the most commonly used endocrine therapy regimen for patients with hormone receptor-positive (HR+) breast cancer (BC) at present, aromatase inhibitors (AIs) reduce the risk of localized and distant recurrence, contralateral BC and secondary cancer, and prolong disease-free survival. Clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huifang, Li, Jie, Gao, Yi, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791186/ https://www.ncbi.nlm.nih.gov/pubmed/36578931 http://dx.doi.org/10.3389/fonc.2022.1054086

Ejemplares similares

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis
por: Zhu, Xue-Ying, et al.
Publicado: (2021)

The Neuro-Immune-Endocrine Connection
por: Stitt, John T.
Publicado: (1987)

Baduanjin’s impact on quality of life and sleep quality in breast cancer survivors receiving aromatase inhibitor therapy: a randomized controlled trial
por: Liao, Jingwen, et al.
Publicado: (2022)

The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
por: Kang, Yi-Kun, et al.
Publicado: (2021)

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study of the Effects of Vaginal Testosterone Therapy
por: Dahir, Melissa, et al.
Publicado: (2014)

Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss
por: Chu, Meiling, et al.
Publicado: (2023)

Immune checkpoint inhibitors: Advances and impact in neuro-oncology
por: Fares, Jawad, et al.
Publicado: (2019)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
por: Seo, Da Hea, et al.
Publicado: (2019)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Psycho-neuro-endocrine-immune mechanisms of action of yoga in type II diabetes
por: Singh, Vijay Pratap, et al.
Publicado: (2015)

Research Progress on the Mechanism of the Acupuncture Regulating Neuro-Endocrine-Immune Network System
por: Cui, Jingwen, et al.
Publicado: (2021)

Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis
por: Bae, Kyeore, et al.
Publicado: (2020)

The Trinity of Skin: Skin Homeostasis as a Neuro–Endocrine–Immune Organ
por: Jin, Rong, et al.
Publicado: (2022)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
por: Fallah, Yassi, et al.
Publicado: (2021)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial
por: Smith, Samuel G, et al.
Publicado: (2023)

Nuclear Mechanisms Involved in Endocrine Resistance
por: Dittmer, Jürgen
Publicado: (2021)

Mechanisms of allosteric and mixed mode aromatase inhibitors
por: Souza, Samson A., et al.
Publicado: (2021)

Study protocol for a randomised controlled feasibility trial of a virtual intervention (STRIDE) for symptom management, distress and adherence to adjuvant endocrine therapy after breast cancer
por: Jacobs, Jamie M, et al.
Publicado: (2021)

Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials
por: de Sire, Alessandro, et al.
Publicado: (2022)

Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis
por: Lee, Young-Kyun, et al.
Publicado: (2020)

Neuro-Endocrine Networks Controlling Immune System in Health and Disease
por: Procaccini, Claudio, et al.
Publicado: (2014)

Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study
por: Ziller, Volker, et al.
Publicado: (2013)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers
por: Wang, Yingnan, et al.
Publicado: (2023)

Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
por: Qin, Ruoyan, et al.
Publicado: (2023)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_36vjsi7dh63rtj0458p6m9s5qu